Skip to content
value.today
Edge Therapeutics, Inc. logo

Edge Therapeutics, Inc.

🇺🇸 New Providence, New Jersey, USAPharmaceuticalsFounded 2009
Total raised
$71 M
3 rounds on record
Latest round
$56 M
Apr 2015
First round on record
Mar 2013
Today
Went public
See the company page

Edge Therapeutics, Inc. is listed today as PDS Biotechnology Corporation: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Edge Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2015$56 MNo. 3$50 to $250 million

Edge Therapeutics, Inc.: Raise no. 3, Apr 2015

Investors in this round

19 investors had bought by the notice of Apr 9, 2015: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Edge Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $56 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$3,301,999
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albert N. Marchio II · Executive Officer
  • Andrew Loch Einhorn · Executive Officer
  • Brian A. Leuthner · Executive Officer, Director
  • Carl J. Soranno · Executive Officer
  • Herbert J. Faleck · Executive Officer
  • Robert Loch Macdonald · Executive Officer, Director
  • Isaac J. Blech · Director
  • James J. Loughlin · Director
  • Kurt J. Conti · Director
  • Robert J. Spiegel · Director
  • Sol J. Barer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Credit Suisse Securities (USA) LLC (CRD 816) · New York, New YorkSold in all US states
  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states
  • Maxim Group, LLC (CRD 120708) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used to pay salaries of some related persons listed in Item 3.”

Signed by Albert N. Marchio II, Assistant Secretary. Source: SEC Form D, newest notice filed Apr 9, 2015. Read the notice at the SEC.

equitySEC
Nov 2014$8 MNo. 2$2 to $10 million

Edge Therapeutics, Inc.: Raise no. 2, Nov 2014

Investors in this round

104 investors had bought by the notice of Nov 13, 2014: 104 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Edge Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $25 M offered; $17 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$595,881
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albert N. Marchio II · Executive Officer
  • Andrew Loch Einhorn · Executive Officer
  • Brian A. Leuthner · Executive Officer, Director
  • Carl J. Soranno · Executive Officer
  • Herbert J. Faleck · Executive Officer
  • Robert Loch Macdonald · Executive Officer, Director
  • Isaac J. Blech · Director
  • James J. Loughlin · Director
  • Kurt J. Conti · Director
  • Robert J. Spiegel · Director
  • Sol J. Barer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used to pay salaries of some related persons listed in Item 3.”

Signed by /s/ Albert N. Marchio II, Assistant Secretary. Source: SEC Form D, newest notice filed Nov 13, 2014. Read the notice at the SEC.

equitySEC
Mar 2013$7 MNo. 1$2 to $10 million

Edge Therapeutics, Inc.: Raise no. 1, Mar 2013

Investors in this round

52 investors had bought by the notice of Mar 25, 2013: 52 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Edge Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $20 M offered; $13 M still to sell
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$600,608
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albert N. Marchio II · Executive Officer
  • Brian A. Leuthner · Executive Officer, Director, Promoter
  • Priya Loch Jambhekar · Executive Officer
  • Robert Loch Macdonald · Executive Officer, Director, Promoter
  • Isaac Loch Blech · Director
  • James J. Loughlin · Director
  • Kurt J. Conti · Director
  • Sol J. Barer · Director
  • Carl J. Soranno · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used to pay salaries of some related persons listed in Item 3.”

Signed by Albert N. Marchio II, Assistant Secretary. Source: SEC Form D, newest notice filed Mar 25, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Edge Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2015).

    SEC Form D · Apr 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2015

That is all the official record says: Edge Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Edge Therapeutics, Inc. are on record.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Edge Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Albert N. Marchio IIPersonnot statednot statedHeld Series C-1 preferred stock (Form 3, 2015)SEC Form 3
Andrew J. EinhornPersonnot statednot statedHeld Series B-1CONVERTIBLE, C and C-1 preferred stock (Form 3, 2015)SEC Form 3
Brian A. LeuthnerPersonnot statednot statedHeld Series C-2 preferred stock (Form 3, 2015)SEC Form 3
James J. LoughlinPersonnot statednot statedHeld Series C-2 preferred stock, director (Form 3, 2015)SEC Form 3
Kurt G. ContiPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2015)SEC Form 3
R. Loch MacdonaldPersonnot statednot statedHeld Series A and C-1 preferred stock, director (Form 3, 2015)SEC Form 3
Robert J. SpiegelPersonnot statednot statedHeld Series C-1 and C-2 preferred stock, director (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 104 investors.

Largest shareholders today

Institutions holding PDS Biotechnology Corporation shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Edge Therapeutics, Inc.
NameRoleNamed in
Albert N. Marchio IIExecutive officerApr 2015
Andrew Loch EinhornExecutive officerApr 2015
Brian A. LeuthnerExecutive officerApr 2015
Carl J. SorannoExecutive officerApr 2015
Herbert J. FaleckExecutive officerApr 2015
Robert Loch MacdonaldExecutive officerApr 2015
Priya Loch JambhekarExecutive officerMar 2013
Brian A. LeuthnerDirectorApr 2015
Isaac J. BlechDirectorApr 2015
James J. LoughlinDirectorApr 2015
Kurt J. ContiDirectorApr 2015
Robert J. SpiegelDirectorApr 2015
Robert Loch MacdonaldDirectorApr 2015
Sol J. BarerDirectorApr 2015
Isaac Loch BlechDirectorMar 2013
Brian A. LeuthnerPromoterMar 2013
Carl J. SorannoPromoterMar 2013
Robert Loch MacdonaldPromoterMar 2013

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.